Polyakova Kseniya I
Budget impact analysis of teriflunomide inclusion as first-line disease modifying drugs (DMD) therapy in the List to ensure patients with relapsing-remitting multiple sclerosis (RRMS) within the programme ‘7 high-cost nosologies’ on the budgets of Russian Federation (RF) federal and regional public authorities in the field of health care.
Budget impact analysis of teriflunomide inclusion as first-line disease modifying drugs (DMD) therapy in the List to ensure patients with relapsing-remitting multiple sclerosis (RRMS) within the programme ‘7 high-cost nosologies’ on the budgets of Russian Federation (RF) federal and regional public authorities in the field of health care.